Atomoxetine Dose Titration
For children and adolescents ≤70 kg: Start atomoxetine at 0.5 mg/kg/day and increase after a minimum of 3 days to a target dose of 1.2 mg/kg/day, with a maximum of 1.4 mg/kg/day or 100 mg/day (whichever is less). 1
For children and adolescents >70 kg and adults: Start at 40 mg/day and increase after a minimum of 3 days to a target dose of 80 mg/day. After 2-4 additional weeks at 80 mg/day, the dose may be increased to a maximum of 100 mg/day if optimal response has not been achieved. 1
Dosing Algorithm
Initial Titration Phase
Children/Adolescents ≤70 kg:
- Days 1-3: 0.5 mg/kg/day (can be given once daily in morning OR divided into morning and late afternoon/early evening doses)
- Day 4 onward: Increase to 1.2 mg/kg/day (target dose)
- Maximum: 1.4 mg/kg/day or 100 mg/day, whichever is less
Children/Adolescents >70 kg and Adults:
- Days 1-3: 40 mg/day
- Day 4 onward: Increase to 80 mg/day (target dose)
- After 2-4 weeks at 80 mg: May increase to 100 mg/day if response inadequate
Critical Timing Considerations
Allow adequate time at target dose before judging efficacy. The evidence shows that atomoxetine's effect size increases substantially over time—from small effect sizes (0.28) at 1 week to moderate effect sizes (0.52) by 26 weeks, with the most pronounced improvement in the 80 mg group (0.82 effect size). 2 Patients should remain at target dose for 4-6 weeks minimum before concluding the medication is ineffective. 3
Real-world data reveals a common pitfall: adult patients are frequently underdosed at approximately 60 mg/day average when the recommended target is 80 mg/day. 3 This suboptimal dosing is associated with poor outcomes and premature discontinuation.
Special Dosing Adjustments
CYP2D6 Poor Metabolizers or Strong Inhibitors
When using strong CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine) or in known CYP2D6 poor metabolizers:
- Children/adolescents ≤70 kg: Start at 0.5 mg/kg/day, increase to 1.2 mg/kg/day only if symptoms fail to improve after 4 weeks AND initial dose is well tolerated
- Children/adolescents >70 kg and adults: Start at 40 mg/day, increase to 80 mg/day only if symptoms fail to improve after 4 weeks AND initial dose is well tolerated
Hepatic Impairment
- Moderate hepatic impairment (Child-Pugh Class B): Reduce initial and target doses to 50% of normal
- Severe hepatic impairment (Child-Pugh Class C): Reduce initial and target doses to 25% of normal
Monitoring Strategy
Close monitoring is essential during the first few months of treatment and at times of dose changes due to the black box warning regarding increased risk of suicidal ideation in children and adolescents. 4 Monitor for suicidality, clinical worsening, unusual behavioral changes, cardiovascular effects (blood pressure, heart rate), and common adverse effects including nausea, vomiting, fatigue, decreased appetite, abdominal pain, and somnolence. 4
Key Clinical Pearls
- Atomoxetine can be taken with or without food and does not require tapering when discontinued 1
- Capsules should be swallowed whole, not opened 1
- Evidence suggests no systematic advantage to exceeding current dose guidelines—doses above 1.2 mg/kg/day show no additional benefit 1, 5
- Sequential, weight-based titration is the recommended approach rather than fixed-dose escalation 4
- Therapeutic plasma concentrations appear to require a threshold of approximately 64-83 ng/mL for clinical response, though routine therapeutic drug monitoring is not standard practice 6